STATERA BIOPHARMA
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch STAB and buy or sell other stocks, ETFs, and their options commission-free!About STAB
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. Its proprietary product toll-like receptor (TLR) agonists in the biopharmaceutical industry with TLR4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532 have applications in mitigation of radiation injury and neutropenia an anemia.
CEOMichael Kevin Handley, MBA
CEOMichael Kevin Handley, MBA
Employees16
Employees16
HeadquartersFort Collins, Colorado
HeadquartersFort Collins, Colorado
Founded2003
Founded2003
Employees16
Employees16
STAB Key Statistics
Market cap14.28K
Market cap14.28K
Price-Earnings ratio—
Price-Earnings ratio—
Dividend yield—
Dividend yield—
Average volume2.50K
Average volume2.50K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$0.0133
52 Week high$0.0133
52 Week low$0.00
52 Week low$0.00
Stock Snapshot
As of today, STATERA BIOPHARMA(STAB) shares are valued at $0.00. The company's market cap stands at 14.28K.
On 2026-03-10, STATERA BIOPHARMA(STAB) stock opened at —, reached a high of —, and a low of —.
The STATERA BIOPHARMA(STAB)'s current trading volume is 0, compared to an average daily volume of 2.5K.
In the last year, STATERA BIOPHARMA(STAB) shares hit a 52-week high of $0.01 and a 52-week low of $0.00.
In the last year, STATERA BIOPHARMA(STAB) shares hit a 52-week high of $0.01 and a 52-week low of $0.00.
People also own
Based on the portfolios of people who own STAB. This list is generated using Robinhood data, and it’s not a recommendation.